Asandeutertinib

甲磺酸艾多替尼

Report date: 2026/02/10 20:00:22

NME

Base Information

Drug NameAsandeutertinib

Drug Alias Name氘代AZD9291卡达沙TY-9591

ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs

Mechanisms of ActionEGFR T790M inhibitors

TargetsEGFR T790M

Therapy Area/IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungMeningeal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesTYK Medicines Inc

China Registration ClassClass 1 Chemical Drug in China

Inactive CompaniesN/A

Active IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungMeningeal Neoplasms

Inactive IndicationsN/A

ATC CodeN/A